Dr. Joshua Feuer MD
Owner, JOSHUA M FEUER
Member of the Healthcare Council
Council Member Biography
Joshua Feuer, MD, FACC, is a board certified Cardiologist in solo private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment and reduction. He has expertise in the diagnosis and treatment of lipid disorders, hypertension, coronary artery disease, congestive heart failure, valvular heart disease and cardiac arrhythmias. Dr. Feuer is a Fellow of American College of Cardiology and the Council of Clinical Cardiology of American Heart Association. He has published several articles on coronary artery disease, congestive heart failure, and pacemakers. (This is me - Update Profile)
Employment History
- 1998 - Unspecified
- Owner, JOSHUA M FEUER
- 1990 - 1998
- Staff Physician in Department of Cardiology, SANSUM CLINIC
- 1988 - 1990
- Staff Physician in Department of Cardiology, Long Beach VA Medical Center
GLG NewsSM Analyses by Joshua Feuer(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
If it seems too good to be true...it probably is.
December 9, 2008
Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com
This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.
-
December 8, 2008
There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.
-
Niacin...it's deja vu all over again.
January 29, 2007
An Old Cholesterol Remedy Is New Again | www.nytimes.com
1. Pfizer Inc, the pharmaceutical giant, halted late-stage trials of the HDL increasing drug torcetrapib after investigators discovered that it increased heart problems and increased death rates in the treated population.
2. Niacin, a B vitamin that increases HDL (the good cholesterol) up to 35%, has largely been ignored by physicians treating hypercholesterolemia and coronary heart disease because it is difficult to prescribe related to the common nuisance, but non-serious side effect of flushing.
3. Statins typically decrease LDL (the bad cholesterol) by 30-50% and cardiovascular events by about 30-40% but one analysis suggests that by decreasing LDL by 40% and increasing HDL by 30%, cardiovascular events could be decreased by 70%.
4. A large trial is underway to test this hypothesis comparing statin therapy alone with combination statin plus niacin therapy. -
August 21, 2006
Mixed thoughts on how generic clopidogrel might impact patients, providers | www.theheart.org
Plavix is (essentially) a one-of-a-kind drug.
Plavix is a critical drug after coronary stenting and is a basic component of Acute Coronary Syndrome treatment according to established guidelines.
A generic clopidogrel is now available at a cost savings of ~30%.
Leading institutions connect with Joshua Feuer through GLG
GLG Study Groups with Joshua Feuer(?)
| Study Group Name | No. Members |
|---|---|
| General Cardiologists (US) | 1327 |
| Heart Failure Specialists (US) | 975 |
| Non-Electrophysiologist Cardiologists (US) | 853 |
| Physicians who Treat Hypertension (US) | 792 |
| Physicians who Treat Arrhythmia (US) | 307 |
GLG Live Meetings with Joshua Feuer(?)
Joshua Feuer has not participated in any GLG Live Meetings.